The clinical evidence

One short program, read honestly

Almost everything genuinely known about CJC-1295 in humans comes from a single development program run by ConjuChem between roughly 2005 and 2006: a phase I pharmacology study, a phase II patient trial that was halted, and supporting animal work. That is a thin base for a drug with a large online following.

This unit reads that evidence carefully. It separates what was actually measured from what is extrapolated, grades the strength of each claim, and is honest about the difference between "no efficacy data" and "negative efficacy data". CJC-1295 mostly has the former, which is a specific and important distinction.